Mydecine Innovations Group (Mydecine Innovations Group) EV-to-EBIT : -0.25 (As of Apr. 25, 2024)

Mydecine Innovations Group EV-to-EBIT Chart

Mydecine Innovations Group Annual Data
	Trend	Dec13	Aug14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					-1.56	-0.21	-2.85	-1.69	-0.42

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-0.59	-0.42	-1.14	-0.68	-0.46

Competitive Comparison of Mydecine Innovations Group's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mydecine Innovations Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's EV-to-EBIT falls into.

Mydecine Innovations Group EV-to-EBIT Calculation

Mydecine Innovations Group's EV-to-EBIT for today is calculated as:

Mydecine Innovations Group's current Enterprise Value is $4.77 Mil.
Mydecine Innovations Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mydecine Innovations Group  (OTCPK:MYCOF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mydecine Innovations Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Mydecine Innovations Group's Enterprise Value for the quarter that ended in Sep. 2023 was $8.13 Mil.
Mydecine Innovations Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mydecine Innovations Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (Mydecine Innovations Group) Business Description